Heimann, Sebastian M., Biehl, Lena M., Vehreschild, Joerg Janne, Franke, Bernd, Cornely, Oliver A. and Vehreschild, Maria J. G. T. (2018). Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis. Am. J. Infect. Control, 46 (9). S. 992 - 998. NEW YORK: MOSBY-ELSEVIER. ISSN 1527-3296

Full text not available from this repository.

Abstract

Background: A recent study reported a reduction in probable/definite central venous catheter (CVC)-related bloodstream infections (CRBSIs) in neutropenic high-risk patients using CVC dressings with a chlorhexidine-containing gel pad. Methods: Based on published data, a health-economic analysis was performed to analyze the economic effect of using CVC dressings with a chlorhexidine-containing gel pad compared to non-chlorhexidine control dressings. A micro-costing approach was used to determine CRBSI-related direct treatment cost factors. Results: Between February 2012 and September 2014, 356 patients (178 patients in both groups) were analyzed. Distribution of probable and definite CRBSI in the chlorhexidine group and control group were 12 (7%) vs 18 (10%) and 9 (5%) vs 21 (12%), respectively (P = .011). Median overall length of stay (25 vs 27.5 days: P=.630) and days on treatment with antibacterials (10 vs 12 days: P = .140) were similar between the chlorhexidine and control groups. The most important cost driver in both groups was treatment on general ward ((sic)4275 [US$ 5173], interquartile range [IQR]: (sic)592 - (sic)6504 [US$ 716 - US$ 7871] vs (sic)4560 [US$ 5518], IQR: (sic)1227 - (sic)8567 [US$ 1485 - US$ 10,367]; P=.120), resulting in median overall direct treatment costs of (sic)13,881 (US$ 16,798) (IQR: (sic)10,922 - (sic)25,457 (US$ 13,217 - US$ 30,807) vs (sic)13,929 [US$ 16,856] [IQR: (sic)11,295 - (sic)23,561 (US$ 13,669 - US$ 28,512); P=.640]). Conclusion: Our study shows similar results in overall direct treatment costs, meaning that higher acquisition costs of chlorhexidine-containing dressings did not translate into higher costs. Expenses were primarily outweighed by a lower rate of probable/definite CRBSI and reduced associated costs. (C) 2018 Association for Professionals in Infection Control and Epidemiology. Inc. Published by Elsevier Inc. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Heimann, Sebastian M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Biehl, Lena M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vehreschild, Joerg JanneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Franke, BerndUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cornely, Oliver A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vehreschild, Maria J. G. T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-175223
DOI: 10.1016/j.ajic.2018.03.006
Journal or Publication Title: Am. J. Infect. Control
Volume: 46
Number: 9
Page Range: S. 992 - 998
Date: 2018
Publisher: MOSBY-ELSEVIER
Place of Publication: NEW YORK
ISSN: 1527-3296
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
RANDOMIZED CONTROLLED-TRIAL; CARE-ASSOCIATED INFECTIONS; CRITICALLY-ILL ADULTS; HEMATOLOGY; ONCOLOGY; OUTCOMESMultiple languages
Public, Environmental & Occupational Health; Infectious DiseasesMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/17522

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item